Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68-Ga FAPI 46

Drug Profile

68-Ga FAPI 46

Alternative Names: 68Ga-FAPi-46; [68Ga]FAPI-46

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Heidelberg
  • Developer SOFIE; University of California
  • Class Antineoplastics; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Cholangiocarcinoma; Gastric cancer; Ovarian cancer
  • Phase 0 Interstitial lung diseases
  • No development reported Breast cancer

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis, Newly diagnosed) in Azerbaijan (IV)
  • 13 Oct 2023 68 Ga FAPI 46 licensed to GE HealthCare worldwide
  • 13 Jun 2023 Aalborg University Hospital plans a phase II trial for Gastric Cancer and Oesophageal cancer (Diagnosis) in September 2023 (NCT05898854)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top